

MDR Genes are Created and Transmitted in Plasmids and Chromosomes to Keep Normal Intestinal Microbiota Alive against High Dose Antibiotics- A Hypothesis

Asit Kumar Chakraborty*

Department of Biochemistry and Biotechnology, Oriental Institute of Science and Technology, Vidyasagar University, Midnapore, West Bengal, India

*Corresponding author: Asit Kumar Chakraborty, Department of Biochemistry and Biotechnology, Oriental Institute of Science and Technology, Vidyasagar University, Midnapore-721102, West Bengal, India, Tel: 91+9339609268; E-mail: chakraakc@gmail.com

Received date: 14 Oct 2017; Accepted date: 01 Dec 2017; Published date: 08 Dec 2017.

Citation: Chakraborty AK (2017) MDR Genes are Created and Transmitted in Plasmids and Chromosomes to Keep Normal Intestinal Microbiota Alive against High Dose Antibiotics- A Hypothesis. J Mol Med Clin Appl 2(1): doi <http://dx.doi.org/10.16966/2575-0305.109>

Copyright: © 2017 Chakraborty AK, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

AMR spread is huge with millions of death due to ineffectiveness of antibiotics. This is happened due to creation of hundreds of *mdr* genes like beta-lactamases (blaTEM, blaCTX-M, blaOXA and blaNDM1), drug acetyltransferases (aacC1, aacA1, cat) and phosphotransferases (aph4) in MDR conjugative plasmids and chromosome. In other mechanisms, drug efflux proteins like tetA/C, acrAB and mexAB kickout drugs from bacterial cytoplasm increasing drug MIC and thus tetracycline, streptomycin, azithromycin, ciprofloxacin became ineffective to destroy pathogenic bacteria. We have investigated here the reason of such widespread creation of *mdr* genes in bacteria which are resident of intestine synthesizing 20 vitamins and complex biomolecules for our body. We have hypothesized that such 2×10^{12} diverse species are killed due to high dose of antibiotic intake since 1940s creating acute health hazard in human which is now balanced by probiotic bifidobacteria and vitamin-B complex capsules supplement. The hypothesis suggested that molecular signalling from intestinal luminal cells (TGF β , IL-10, IL-22) as well as from bacteria (LPS, vitamins, butyrate) orchestrated to preserve symbiosis relation between human and bacteria. Vitamins are converted into pro-vitamins (FADH₂, NADH⁺, THFA, Biotin, B12, TPP etc.) needed for every steps of >30000 enzymatic reactions in human cells. Thus MDR bacteria will be the resident of intestine favouring vitamin biosynthesis and immune-modulation needed for normal human metabolosome. Indeed *mdr* genes are abundantly created in plasmids and chromosomes with further mutations of target genes (rRNA, ponA, porB, gyrAB, parC) and likely all are to protect gut microbiota to save human from extinct. Thus with time all bacteria will be drug resistant and infections should be controlled by heterogenous phyto-antibiotics, gene medicines, phage therapy and DNA nanocarriers for toxic drug delivery.

Keywords: AMR; Antibiotic void; Gut microbiota; Vitamin synthesis; Gene rearrangement; MDR genes

Introduction

The existence of microbes were described until Von Leeuwenhoek observed microorganism through his microscope in 1680s followed by eminent microbiology work of Louis Pasteur and Robert Koch in the 1850s [1]. The antibiotic principle was discovered in 1926 by Alexander Fleming but it took until 1943 for large scale production and supply of penicillin drug for peoples [2]. So mass peoples were taken antibiotics after World War II and within last 60 years we eradicated gut microbiota so drastically that save your soul worked signalling from human and bacteria both to create *mdr* genes many fold. It is unbelievable to think that penicillin, streptomycin, tetracycline, chloramphenicol, rifampicin, azithromycin, ciprofloxacin, cefotaxime, sulfamethoxazole, trimethoprim, are not killing bacteria (Figure 1 for antibiotic structures). Those bacteria are termed as superbugs as highly resistant to at least three groups of different antibiotics. All antibiotic groups are different structures and their derivatives are sometime gave unique side chains producing better drugs but all in vain as ultimately drug resistant genes modified due to mutations or a new isomers appeared that destroy the antibiotic easily than expected (Figure 2 for many MDR Genes). Dr. Selman Walksman's streptomycin worked very well to clear TB in 1950s but now XRD-TB increased many fold in India and abroad. MDR *Mycobacterium tuberculosis* drug resistant today with *strA/B*, *arr3*, *katG* *mdr* genes and mutations in the ribosomal genes *rpsL*, *rplC* and *rrs* as well as *pncA* gene involved in pyrazinamide resistance [2,3].

The length of conjugative plasmids are expected 70-80kb (62kb F'-plasmid + 5-15kb R-plasmid) but now many recombinations have produced 100-500kb plasmids with 5-15 *mdr* genes, >10-20 Tra conjugative genes and other 10-20 new genes whose functions remains to be elucidated [4]. Surely we find topoisomerase III, *parA*, *Uvr3*, *parC*, Transposons and IS-elements (Tn3, IS-26), ABC transporters and metal resistant genes (*terA/B/C*, *CopA*, *MerB/C/X*) in most MDR conjugative plasmids (Figure 3 for structure of prototype large MDR conjugative plasmid in superbugs). A 150kb IncA/C plasmid pMRV150 in *Vibrio cholerae* 0139 strain was found resistant to common antibiotics, ampicillin, tetracycline, gentamycin and chloramphenicol. A IncC hybrid 165kb plasmid in *Proteus mirabilis* was discovered in 2017 with 15 *mdr* genes including most deadly blaNDM-1 and blaCTX-M-65 and indicated that how severe recombination was facilitated in the human intestine during antibiotics exposure [5-8].

The drug industry is always run to make better derivatives of existing drug like Benzyl penicillin. So ampicillin and amoxicillin semi-synthetic drugs were prepared in 1960s to overcome the action of penicillinase enzyme (amp gene, discovered in *Escherichia coli* cloned plasmid pBR322 and sequenced in 1965) [2]. However, blaTEM-1 (protein id. AAB59737) and blaSHV (protein id; AAD37412) enzymes inactivate ampicillin. So oxacillin derivatives were prepared but soon blaOXA-1 enzyme (protein id: AFG30109) was developed that destroy oxacillin and ampicillin but Class-D higher beta-lactamase derivatives like OXA-23, OXA-48 were more potent and most beta-lactams were inactivated. Similarly,




Figure 1: Structures of diverged antibiotics that are now useless in superbug infections [14].




Figure 2: Classification of diverged multi-drug resistant (mdr) genes that destroy all antibiotics described in Figure 1 by different mechanisms.




Figure 3: Structure of a large MDR conjugative plasmid. Such plasmids present in superbugs containing 10 mdr genes and 20 conjugative genes including metal resistant genes and many IS-elements and transposons involved in gene transfer and rearrangement. The plasmid accession numbers are: NC_018107b (353kb), NC_022078 (317kb), LN555650 (299kb), KC543497 (501kb), JN420336 (267kb), CP007558 (272kb), CP011634 (227kb) and FJ628167 (151kb). Un means unknown genes and Tra is conjugative genes.

blaCTX-M (protein id: ABN09669) efficiently hydrolyses all derivatives of cehalosporins including cefoxitin, cefotetan, ceftriaxone and cefotaxime. In 2009 blaNDM-1 beta-lactamase (protein id: AGC54622) was discovered in *Escherichia coli* and *Klebsiella pneumoniae* plasmids. Such enzyme hydrolyses the potent carbapenem drugs like imipenem, dorripenem including cefotaxime and ampicillin drugs (see, Figure 4 for gradual discovery of penicillinases, cephalosporinases and carbapenemases) [9].

Most bacteria in sea, river and rain water are not only resistant to beta-lactams but also to tetracycline, streptomycin, vancomycin, azithromycin and so many others (see Figure 5) [10,11]. However, tetracycline resistant determinants are also many fold: (a) MFS drug efflux type enzymes; tetA (protein id: CAA53389), tetC (protein id: AGL61405) (b) tetracycline binding proteins like tetM, tetO, tetS that induce ribosome protection and (c) tetracycline modification enzyme like tetX that acts in presence of O₂ and NADPH [2]. We characterized the Kolkata environmental superbugs that located in drain water, street rain water, Digha sea water (Bay of Bengal) and most importantly Ganga River water and all were resistant to ampicillin and amoxicillin as well as gentamycin, streptomycin and ciprofloxacin [11,12]. As imipenem, vancomycin, amikacin, colistin, ceftriaxone lomofloxacin and azithromycin resistant species were frequent, it help us to thought differently (see, Figure 5 and Table 1). Such conclusions are immerged after carefully studying the multiple *mdr* gene isomers at the genetic label and drug sensitivities which shows obscure and unbelievable pressure likely generated in vivo to create *mdr* genes with all possible combinations of protein primary amino acid sequences (see, Table 1) [4,13,14]. We have discussed here the rationally of antibiotic void creating an antibiotic dark age due to overuse of antibiotics. We have pinpointed the odd that we misconceptually have killed all intestinal symbiotic bacteria that help us to life and now we need alternate to antibiotics for better treatment of MDR bacterial infections.

Methods

Isolation of multidrug-resistant bacteria

Water from Ganga river was collected at Babughat (Kolkata 700001), at Howrah station ghat (Howrah 711101) and Rain water was collected at South Kolkata (Kolkata 700032). 100µl water spotted onto LB-1.5% plates in presence of single or all four antibiotics cocktails containing tetracycline, choramphenicol, ampicillin, azithromycin, ciprofloxacin and streptomycin. Individual colony was picked up and was grown in presence of antibiotic (ampicillin). The water from Ganga River, Kolkata streets and famous railway stations after rain in monsoon seasons (June-July) gave very distinct drug resistant colonies in presence of 50µg/ml of ampicillin and amoxicillin with 4500-5500 cfu/ml of water [12]. The cfu/ml of water were reduced to five fold in case of tetracycline and azithromycin at 20µg/ml and 50µ/ml respectively, where as reduced to 49 fold with 34µg/ml chloramphenocol and 50µg/ml streptomycin. In presence of beta-lactamase inhibitors cavulinic acid and sulbactam, cfu/ml further reduced to ~50 cfu /ml of water. Similarly inclusion of three antibiotics tetetrcyline, ampicillin, chlormphenicol, streptomycin in combination produces only 10-20 cfu/ml water. Further, imipenem resistant species were found rare with only 0.2-0.3 cfu/ml of Ganga River water.. The results indicated that everywhere had MDR-bacteria and 30-40% was ampicillin and amoxycillin resistant as well as <1-2% were superbugs (MDR but % XDR was low and no PDR was detected). As for example, imipenem resistant bacterial species were present extremely low (~ 0.003%). According to law, MDR bacteria must be resistant to at least three different groups of antibiotics. So the percentage of MDR-bacteria that resistant to three drugs, ampicillin, streptomycin and tetracycline was also as low as only 0.2%. Then we have tested the pure rain water (collected on 4th floor roof keeping a 50 ml plastic tube inside a 500 ml beaker) and it has also very similar numbers of bacteria indicating as the

Table 1: Antibiogram and 16S rRNA sequencing to confirm MDR bacterial Genus and species. rRNA genes were deposited into NCBI GenBank [30]. All bacteria are resistant to ampicillin but sensitive to imipenem. Imipenem resistant bacteria was recovered from 10 ml Ganga River water and Digha sea water but was absent in rain water [2].

Antibiogram of the isolated and characterized MDR-bacteria from Kolkata		
Bacteria/Source	Accession no	Major Drug Resistance Patterns
<i>Escherichia coli</i> KC-1 mdr (Ganga river)	KU898253	Methicillin, Tetracycline, Streptomycin, Ciprofloxacin, Cotromoxazole, Lomofloxacin, Vancomycin, Amikacin, Linezolid
<i>Escherichia coli</i> KR-1_mdr (Kolkata rain)	KY769883	Methicillin, Cefotaxime, Aztreonam, Azithromycin, Chloramphenicol, Tetracycline, Vancomycin, Amikacin, Streptomycin, Cotrimoxazole
<i>Pseudomonas aeruginosa</i> DB-1 mdr (Kolkata street)	KY769875	Metthicillin, Cefotaxime, Ceftriaxane, Azithromycin, Chloramphenicol, Vancomycin
<i>Escherichia coli</i> KC-2_mdr (Kolkata street)	KY769878	Methicillin, Tetracycline, Amikacin, Vancomycin, Cotrimoxazole, Streptomycin, Azithromycin
<i>Escherichia coli</i> KT-1_mdr (Kolkata street)	KY769881	Metthicillin, Cefotaxime, Tetracycline, Ciprofloxacin, Chloramphenicol, Azithromycin, Gentamycin, Vancomycin, Amikacin, Linezolid
<i>Escherichia coli</i> KT-2_mdr (Ganga river)	KY769882	Metthicillin, Vancomycin, Lomofloxacin, Cotrimoxazole, Azithromycin, Amikacin
<i>Phenalkaligenes</i> sp. KG-1_mdr (Ganga river)	KY769879	Neomycin, Gentamycin, Azithromycin, Ciprofloxacin, Polymyxin, Vancomycin
<i>Stenotrophomonas</i> sp. KGB-1_mdr (Ganga river)	KY769880	Methicillin, Azithromycin, Tetracycline, Streptomycin, Cotrimoxazole, Vancomycin
<i>Escherichia coli</i> KTB-1_mdr (Kolkata street)	KY769877	Methicillin, Tetracycline, Cotrimoxazole, Neomycin, Streptomycin, Azithromycin
<i>Pseudomonas aeruginosa</i> DG-2_mdr (Digha sea)	KY769876	Cefotaxime, Ciprofloxacin, Tetracycline, Streptomycin, Cotrimoxazole, Neomycin




Figure 4: Discovery of β -lactams and β -lactamases. It appears any insult of gut microbiota by antibiotics will follow drug resistant with new mdr gene synthesis in the intestinal bacteria. About 20 types distinct β -lactamases with few thousand mutations were detected and. It appears bla genes are also acquired enhancer-repressor elements and are bla genes are now induced by β -lactams. So use of more antibiotic means more beta-lactamase synthesis increasing MIC and is likely health risk [4].




Figure 5: (A-B) Multidrug resistant assay using HI-Media antibiotic papers; (C) cleavage mechanism of beta-lactam by beta-lactamase enzyme; (E) CAT gene assay to demonstrate acetylation of chloramphenicol and (E-F) crystal structures of blaTEM and blaKPC enzymes [4,14].

major source of bacterial contamination on streets, ponds and sea. This means if any superbug got escape from clinics to environment by physical calamity like storm, tide, flood or earth quake and then bacterial spore could be spread to anywhere by wind and would fall during rain affecting mass populations. The old city like Kolkata has damage sewage system and floods everywhere of the city during monsoon causing nail or skin infections. We have isolated few strains of gram-negative superbugs (KA1, KR1, DG1, KC1, KT1, and KG1) that are resistant to at least three different groups of drug (e.g. ampicillin, streptomycin, cefotaxime, azithromycin,

ciprofloxacin, tetracycline or chloramphenicol). The nomenclature has given as follows: "K" means Kolkata origin, KA1 means ampicillin selected 1st then mdr-selected; KR1 means rain source and mdr-selected, KC1 means 1st chloramphenicol selected then mdr selected; KT1 means 1st tetracycline selected then mdr-selected, KG1 means from Ganga river water. Mdr-selection usually mean LB-agar plate contains a mixture of four antibiotics at 50-100 μ g/ml concentration (ampicillin, streptomycin, ciprofloxacin, azithromycin). The bacterial counts in water sources from open drain, rain water and Ganga River at Kolkata were compared and

surprisingly high incidence (~ 40%) of penicillin drug resistant bacteria were found everywhere. Most of the bacteria were *Escherichia* rod and flagellates and *Pseudomonas* as demonstrated by electron microscopy and also could form circular spores. Surprisingly, KG-1, KT-1 or KC-1 strains are resistant to 12 Hi-Media antibiotic strips according to CLSI standard [11].

Preparation of genomic DNA

The genomic DNA was isolated from 3 ml ON culture in LB media (10gm NaCl+10gm Bactotryptone+5gm Yeast extract/L water at P^H 7.4) in presence of 100µg/ml ampicillin or 40µg/ml tetracycline. The bacteria were pelleted at 5000 rpm and pellet was dissolved in TE buffer and incubated overnight in presence of 0.1% SDS and 20µg/ml Proteinase-K. Then extracted with chloroform: isoamyl alcohol (24:1) and precipitated with 2 volumes of 99% ethanol. Genomic DNA was dissolved in TE buffer and treated with DNase free RNase A (1µl of 20mg/ml) for 15 min at 37°C, extracted with phenol: chloroform: isoamyl alcohol (25:24:1) and DNA precipitated with 1/9 volume 3M sodium-acetate P^H 5.2 and 2 volume ethanol.

Preparation of plasmid DNA

The plasmid DNA was isolated from overnight culture using Alkaline-Lysis Method. Simply, to bacterial pellet 100 solution-I was added and mixed. Then 200µl of cold Solution-II added to make transparent solution and then 150µl cold of Solution-III was added and mixed well. After 10 min the solution containing huge white coloured precipitate of chromosomal DNA-cell debris were removed by centrifugation at 10000rpm for 10min. To clear solution then added 1 ml 99% ethanol and centrifuged at 10000 rpm for 10 min at 4°C. Plasmid DNAs from four such preparation were combined and the tRNAs were removed by RNase A treatment as above and finally plasmid DNA was dissolved in 50µl TE buffer and was stored at -20°C. 0.8% agarose gel electrophoresis in 1x TAE buffer at 50V for 4-6 hrs was performed to see the plasmid DNAs after staining in 0.5µg/ml ethidium bromide and UV illumination [11].

Primers used in to detected beta-lactamase and drug efflux genes			
Name	Sequence of the primers	Tm	size
P27F	5'-AGA GTT TGA TCC GAA CGC T-3'	62°C	1.4kb
P1392R	5'-TAC GGC TAC CTT GTT ACG ACT TCA-3'	65°C	
cmrF	5'-TTC GTT AGT CTG CCG TTG CT-3'	56°C	323bp
cmrR	5'-ATC GCT GGC AAA CAG GGT TA-3'	57°C	
blaVIM-F	5'-CAG ATT GCC GAT GGT GTT TGG-3'	57°C	519bp
blaVIM-R	5'-AGG TGG GCC ATT CAG CCA GA-3'	61°C	
tetF	5'-CTT CGC TAC TTG GAG CCA CT-3'	57°C	910bp
tetR	5'-GCA GAC AAG GTA TAG GGC GG-3'	57°C	
acrAB-F	5'-ATG CTC TCA GGC AGC TTA GCC-3'	59°C	.1kb
acrAB-R	5'-TGT CAC CAG CCA CTT ATC GCC-3'	59°C	

The 1.4 kb rRNA DNA amplified by sequence specific forward primer 5'-AGA GTT TGA TCC GAA CGC T-3' and reverse primer 5'-TAC GGC TAC CTT GTT ACG ACT TCA CCC C-3' using Taq DNA polymerase. The PCR reaction contained (30µl) 50ng genomic DNA, 0.25mM dXTPs, 2mM MgCl₂ and 1Unit Taq polymerase, and amplification cycles were 35 for 94°C/30sec, 52°C/45sec, 72°C/2min. The 1.4 kb band was excised from gel and 20-50 ng DNA was used for di-deoxy colour chain termination reaction for DNA sequencing by Xcelris Labs Limited and SciGenom Labs.

BLAST search and GenBank submission

Sequence obtained by forward and reverse primers were aligned and homologies were detected by BLAST (www.ncbi.nlm.nih.gov/blast). Then the bacteria was recognized for genus and sometime species and deposited to GenBank and accession numbers were obtained (KY769875-KY769883). The papers and reviews were obtained using Pubmed (www.ncbi.nlm.nih.gov/pubmed) and individual DNA/Protein sequence

(plasmids and genomes and enzymes) was obtained by nucleotide/protein search (www.ncbi.nlm.nih.gov/nucore//nucleotide//protein). Individual *mdr* gene was sorted and seq-2 DNA analysis was performed to detect the chromosomal and plasmid position. Then the individual accession number was searched for DNA sequence of plasmid and chromosome to check the ATG and TAA codons [2,14].

Results and Discussion

We confirmed in 1940s that we got magic bullet “antibiotics” and we could withstand World War I and II madness thereafter with removing bugs from our body by Fleming’s and Walksman’s magic bullets “penicillin and streptomycin”. In 2017, we confirmed that all antibiotics had created problems in our body by signalling to make *mdr* genes highly so that repeated dose of antibiotics would not be able to kill all microbiota in our intestine. It seems bacteria are very happily rearranged its DNA to make 100 of *mdr* genes in plasmids and integrons which now have recombined with F⁺-plasmid to make super conjugative MDR plasmids that could donate *mdr* genes easily to all bacteria. Thus >95% of bacteria isolated from our body are now ampicillin and tetracycline resistant [11,12].

Table 1 shows the antibiotic sensitivities of MDR bacteria isolated from Kolkata water resources and drug resistant is rampant. Scientists have predicted that *mdr* genes could be present in bacteria before the discovery of antibiotics in 1928 due to competition between bacteria and fungi [15]. We assume such genes are very similar to modern *amp*, *tet*, *neo*, *blaNDM-1*, *blaOXA-23*, *blaCTX-M-1*, *aacA4* (protein id: AEZ05102), *aacC2* (protein id: AAA21890), *aphA2* (protein ids: CAA25854, AAA85506), *aadA1* (AAK13440), *sul1*, *arr*, *mcr-1* (protein id: ARD68168), *catB3* (protein id: AAD20921) etc. genes that are generated due to over exposed antibiotics in human and animal as well as contamination of such drugs in water from industry, agricultural land and human excreta (Figure 6) [3-5]. Question arises if bacteria are needed for human development is known, then why drastic antibiotic use is permitted by physicians to remove gut micro-flora? Of course pathogenic bacteria should be eliminated by antibiotics but probiotic bacteria should be taken instantly after each antibiotic exposure. Now >40% sea and river water *Escherichia coli* and >95 % clinical isolates are resistant to ampicillin and amoxicillin, the wonder drugs that are used since 1943 [16-18]. Why not scientists have tried to understand that 20 vitamins and many complex bio-molecules are produced by bacteria without which we cannot live one minute because coenzymes are needed for glycolysis, TCA cycle, ATP generation and metabolisms of DNA, RNA, protein and lipid [19-21]. Vitamin-B and vitamin-A complex are approved for treatment but few peoples know about it and doctors are also not very keen to give message to patients about it particularly in poor nations. Recently, researchers have suggested that reduction of antibiotics use will lower the spread of drug resistant bacteria and G-20 action plan on AMR tells the truth. Moreover, several high quality research from US Human Microbiome Project (HMP), European Metagenomics of the Human Intestinal Tract (MetaHIT) and others have demonstrated the beneficial functions of the normal gut flora (>35000 species) on health (Figure 6). Such microorganisms express many hydrolases, glycosyl transferases and polysaccharide lyases as in *Bacteroides thetaiotaomicron* about 260 hydrolases have been reported that even are not present in 23 pair human chromosomes [22]. Similarly other microorganisms like *Bacteroides*, *Roseburia*, *Bifidobacterium*, *Fecalibacterium* and *Enterobacterium* are involved in carbohydrate metabolism with production of butyrate, acetate and propionate nutrients that are involved in molecular signalling to intestinal cells (Figure 7) [23]. Other study indicated that oxalate was removed by *Oxalobacter formigenes* and *Lactobacillus species* preventing kidney stones. Intestinal *Escherichia coli* and *Bacteroides intestinalis* have role in modulation of bile acids into deoxycholic acids and lithocolic acids

[22,23]. Similarly, pathogenic bacteria like *Helicobacter*, *Vibrio*, *Salmonella* in stomach, *Enterococcus*, *Bacteroides fragilis* in luminal, *Clostridium sp.*, *Prevotella sp.* and *Akkermansia muciniphila* in intestinal mucus layer are important in bioconversion, vitamin biosynthesis and immune-modulation (Figures 7 and 8) [13]. Nevertheless, roles of *Helicobacter pylori* and *Pseudomonas aeruginosa* in promoting cancer have been established and in peoples mind first and last thing is take sufficient antibiotics to clear unseen stomach and intestinal bacteria (Figure 6). Technology like microbial culturomics help to detect and isolate previously uncultured gut bacteria for typing against hundred of antibiotics and bacteriophages that again may facilitate MDR generation with new gene creation [14]. Gut microbiota populations greatly vary with age but most bacteria could be found within age 3 and changes in such diverse populations cause serious health hazards like obesity, cancer, diabetes and others (Figure 6). Rapid and repeated destruction of such microbiota by antibiotic uses since 1940s have caused serious communications gaps by LPS and vitamin synthesis. Now more and more new genes will be seen in plasmids (each 100-500kb MDR conjugative plasmid carry ~20 unknown genes) as rapid DNA sequencing methods by Illumina (SanDiego), Roche 454 pyro-sequencing, HTS technology like solid system (Applied Biosystems), and Ion platforms (Life Technologies) are available to all researcher with a reduced cost [24,25]. No doubt free cost of NCBI database and BLAST search technologies now have facilitated bacterial genome sequencing at every college and research institution of the developing countries (Table 2 for plasmid accession numbers). We also know that without *amp*, *neo cat*, *aac*, *pac* genes no vector

could be devised and similarly few thousand vectors are used everyday where huge antibiotic are used for recombinant bacterial selection. So ampicillin, streptomycin, chloramphenicol, neomycin and tetracycline are used few decades largely increased the concentration of drugs into environment. Critic argue that such bacteria (*E. coli* DH5 α) have genetic mutations and incapable of conjugation and recombination [11-13]. My point is scientific development favours industry and business benefiting developed countries but poor countries have to face problems due lack of infrastructure and sufficient fund to overcome the health issues [2]. We argue to stop molecular biology and recombinant technology in every corner of this globe and perhaps one good centre in each big countries like USA, Canada, Germany, India, China, Brazil etc. is sufficient and that will reduce antibiotic use and artificial genetic recombination. G-20 Nations acted at Germany recently (July, 2017) in quite similar way but not exactly the same and we need more rigorous one Nation platform reducing unnecessary use of toxic chemicals in research [26]. Pesticides, paints, detergents should be biocompatible and user friendly as we saw poor farmers are using repeated pesticides in farmlands hoping good crops and now also are using bio-fertilizers (bacteria) as all nitrogen fixing bacteria have died in farmlands due to high dose of antibiotics and insecticides. In other words, stop this Earth from chemical toxicities [27]. Otherwise, MDR bacteria horror will be increasing with millions of such death in every country onwards 2050! I have surprised to see how the Ganga River water at Kolkata (West Bengal, India) has contaminated with MDR bacteria resistant to most common antibiotics including most deadly

Table 2: Localization of many *mdr* genes in MDR conjugative plasmids of diverse pathogenic bacteria. GenBank search indicated as high as 5-15 *mdr* genes located in single large plasmid indicating how selective presser was mounted in bacteria to create *mdr* genes and its accumulations in single plasmids. Our data previously pinpointed the presence of large as well as small plasmids in MDR bacteria [12]. *Bla* genes lyses penicillin drugs, *aac* and *aph* genes acetylate and phosphorylate drugs respectively, and drug transporter like *tet*, *mcr*, *macAB*, *mexAB* (MFS, RND) kick out drug from bacterial cytoplasm. Such composite plasmids are created in acute stress of intestinal cells due to lack of vitamins during high dose antibiotics treatment on gut microbiota [2,12].

Multi-drug resistant (<i>mdr</i>) genes in bacterial conjugative large Plasmids				
Accession number	Size (kb)	Beta-lactamases, drug transporters, metal resistant and antibiotic inactivating enzymes were found	GenBank Year	MDR Pathogens
NC_018107	353	<i>aac3'</i> -Ild, <i>aph2'</i> , <i>terA/C/F</i> , <i>Sul1</i> , <i>ANT3'</i> -Ia, <i>dhfr</i> , <i>blaCTX-M-3</i> , <i>aacA4</i> , <i>blaSHV-12</i> , <i>aph3''</i> , <i>blaTEM</i>	2017	<i>K. oxytoca</i>
NC_022078	317	MFS, <i>merBC</i> , <i>cat</i> , <i>sul1</i> , <i>aac3'</i> , <i>cmr</i> , <i>tetA</i> , <i>tetG</i> , <i>ABC</i> , <i>blaKPC</i> , <i>blaCTX-M-24</i> , <i>blaVEB-3</i> , <i>aph3'</i> -Ia, <i>copB/C</i>	2017	<i>K. pneumoniae</i>
LN555650	299	<i>terA/C/F/W/Y</i> , <i>blaAmpC</i> , <i>sul1</i> , <i>arsB</i> , <i>silA</i> , <i>strA</i> , <i>dhfr</i> , <i>catA1</i> , <i>blaACC-1</i> , <i>aadA1</i> , <i>aacA4</i> , <i>blaVIM-1</i>	2015	<i>S. enterica</i>
KM877269	249	<i>aad</i> , <i>floR</i> , <i>hph</i> , <i>aac6'/3'</i> , <i>blaOXA-1</i> , <i>catB</i> , <i>arr3</i> , <i>sul1</i>	2015	<i>S. enterica</i>
CP011634	227	<i>blaOXA</i> , <i>aad</i> , <i>blaTEM</i> , <i>merC</i> , <i>aad</i> , <i>sul1</i> , <i>aac</i> , <i>blaTEM</i>	2015	<i>K. oxytoca</i>
HG530658	223	<i>terW</i> , <i>blaACC-1</i> , <i>strA</i> , <i>aadA2</i> , <i>aac3'</i> , <i>rcnA</i> , <i>pcoS</i>	2015	<i>E. coli</i>
LN850163	167	MFS, AAA <i>tetA</i> , <i>cat</i> , <i>blaTEM</i> , <i>macAB</i> , <i>blaCTXm</i>	2015	<i>E. coli</i>
KT185451	151	<i>blaTEM/CTXm/SHV12/KPC</i> , <i>merD</i> , <i>blaNDM1</i>	2015	<i>K. pneumoniae</i>
KF705205	134	<i>hph</i> , <i>strA</i> , <i>aac(3')-IV</i> , <i>tetA</i> , <i>blaTEM-1</i>	2015	<i>S. enterica</i>
KP893385	137	<i>blaCTXm-65</i> , <i>blaKPC-2</i> , <i>blaSHV-12</i> , <i>blaTEM-1b</i>	2015	<i>K. pneumoniae</i>
KC543497	501	<i>Ter2</i> , <i>blaOXA-10</i> , MFS, <i>blaTEM8</i> , <i>ble</i> , <i>catB8</i> , <i>aac</i>	2014	<i>P. aeruginosa</i>
NC_012690	148	<i>flo^R</i> , <i>tetA</i> , <i>strB</i> , <i>sul2</i> , <i>blaAmpC</i> , <i>sul1</i> , <i>aph</i> , <i>blaTEM1</i> ,	2014	<i>E. coli</i>
HG941719	135	<i>bla_{TEM1}'</i> , <i>aadA5</i> , <i>mphA</i> , <i>bla_{CTX'}</i> , <i>bla_{OXA'}</i> , <i>aac6</i> , <i>sull</i> , <i>tetA</i>	2014	<i>E. coli</i>
NC_020087	133	<i>aphA</i> , <i>hph</i> , <i>tetA</i> , <i>blaLAP₂'</i> , <i>dhfrXII</i> , <i>ble</i> , <i>qnrS1</i>	2014	<i>K. pneumoniae</i>
NC_019375	180	<i>blaVIM</i> , <i>aacA7</i> , <i>dhfr</i> , <i>ANT3'</i> , <i>SHV-5</i> , <i>sul1</i> , <i>aph3'</i>	2014	<i>P. stuartii</i>
NC_022522	168	<i>blaCTX-M25</i> , <i>aacA4'</i> , <i>strB</i> , <i>strA</i> , <i>aadB</i> , <i>blaOXA21</i>	2014	<i>S. enterica</i>
NC_019121	166	<i>blaAmpC</i> , <i>sul2</i> , <i>tetA</i> , <i>flo^R</i> , <i>TniB</i> , <i>mcp</i> , <i>hygB</i> , <i>aph</i>	2014	<i>S. enterica</i>
CP007558	272	<i>blaAmpC</i> , <i>ABC</i> , <i>sul1</i> , <i>blaTEM</i> , <i>aad</i> , <i>ble</i>	2014	<i>C. freundii</i>
AP012055	250	<i>blaNDM₁'</i> , <i>ccdA</i> , <i>ccdB</i> , <i>aadA2</i> , <i>catA1</i> , <i>qacA1</i>	2013	<i>K. pneumoniae</i>
AP012056	141	<i>Aac3/6</i> , <i>catB4</i> , <i>tetA</i> , <i>sul2</i> , <i>blaOXO/CTX/TEM</i> , <i>strB_A</i>	2013	<i>K. pneumoniae</i>




Figure 6: Gut microbiota populations (2×10^{12}). Such bacteria are necessary for vitamin synthesis and many exmetabolites trigger IL6, IL22, IL26 and LPS production which send signal to brain for immunoregulation between intestinal cells and bacteria. Research indicated that imbalance in bacterial populations may facilitate modern disease epidemics like cancer, autism, diabetes and cardiovascular diseases. Chronic inflammation leads to tissue destruction and complications. Chronic low-grade inflammation is associated with obesity and metabolic dysfunction (insulin resistance). Increased LPS levels can stimulate eCB1 receptors, which activates the endocannabinoid and promotes adipogenesis [19].




Figure 7: Symbiotic relation between gut bacteria and intestinal cells to produce inflammatory cytokines. Immunomodulins, vitamins and SCFAs modulate intestinal cells to produce pro-inflammatory cytokines (IL-6, IL-10, TGFβ, IL-23, IFN-γ) and anti-inflammatory cytokines (IL-10, TNF, IL-12, IL-17). Our hypothesis have suggested that such cytokines are also released by macrophages and dendritic cells inducing molecular changes in bacteria to create gene rearrangements and *mdr* gene creation to save gut microbiota [20,21].




Figure 8: Adaptive immune-regulation by gut bacteria. Microbiota regulates intestinal immune responses primarily through the production of pathogen-associated molecular patterns (PAMPs) and metabolic by-products. Microbiota stimulation leads to B cell switch to IgA, regulatory T cell induction, and T cell differentiation to Th17. Translocation of bacteria and bacterial products, immune activation and proinflammatory cytokine production likely cause gene rearrangement to create *mdr* genes in intestinal bacteria with stress induced by antibiotics [22,23].

drugs like imipenem, amikacin, linezolid, lomofloxacin, vancomycin, cefotaxime, methicillin and ceftioxane. MDR bacteria present in air dust particles and thus travel to any place with wind and fall in any place during rain. MDR bacteria has been detected in many asymptomatic animal and human with no detection of injury.

So we conclude: (i) Penicillin, cephalosporin and carbapenem drugs are highly eradicated gut microbiota and thus various isoforms of drug resistant beta-lactamases are generated; (ii) Tetracycline, streptomycin and sulfamethoxazole use are rampant and similarly *tetA*, *tetB*, *tetC* and *tetM* as well as *strA/B* and *sul1/2/3* genes are very frequent in plasmids and chromosomes (Table 2); (iii) Acetyl/Phospho/Adenyl transferases (*cat*, *aac*, *aad*, *aph* genes) are also frequent in plasmids due to over exposure of chloramphenicol, aminoglycosides (erythromycin and azithromycin) and fluoroquinolones (ciprofloxacin); (vi) many drug efflux genes accumulated, mutated and activated in plasmids but also in bacterial chromosome (Table 3); (v) thus any drug in over use will follow drug resistant (like, NDM-1, Mcr-1 genes) in human and animal because sensing mechanisms for gene rearrangement and *mdr* gene generation are protected from both sides i.e. bacteria and host (human and animal) without which both will be extinct.


G-20 Nations and WHO action Plans are important to reduce antibiotic use but other actions may be important against MDR horror [11,13]: (i) Immediate action plans are needed to stop generation of complex antibiotics derivatives that create more pressure on bacterial metabolism which act as catalysis for new gene creation; (ii) Mandatory use of vitamin complexes is necessary and combination of synbiotics with antibiotics is must to save the human cells from crisis of metabolosome; (iii) Direct coenzymes like NADH, FADH₂, THFA and PLP may help patients and will reduce the *mdr* gene generation and must be supplied to patients during each antibiotic therapy; (iv) MDR-bacteria with 5-15 *mdr* genes in MDR conjugative plasmids and chromosomes are very frequent now and phage therapy is a new frontier for medicine, (v) Complex biomolecules made by microbiota like colipain, linoleic acid, p-cresol etc. will be implement in diet of patients and such research will be accelerated to keep human in this Earth for long time and (6) Phyto-antibiotics in combination with gene medicines (SiRNA, Ribozymes, CASPER-CAS and others) and drug nanocarriers will be the future effective treatment options (Figure 9).

Conclusion

It is thus concluded that use of antibiotics without immediate probiotics or vitamin supplementation signalled to bacteria to generate *mdr* genes in household gut bacteria that will be thus able to continue synthesis of vitamins and coenzymes as well as other complex biomolecules absolutely needed at every point of human metabolosome [11, 28]. However, the signalling nature of intestinal cells to bacteria has not clearly understood. Active research is needed to know such signalling but antibiotic use also must be regulated. All points of research indicated that drug resistant bugs are more prominent at the site of industry that synthesis it and such contamination of drugs in many rivers is shocking [29-31]. Colistin is one of the last resort superbug drugs after imipenem (which lost in 2009 due to blaNDM-1 discovery & spread) but recently colistin was taken out from drug regime as Mcr-1 gene discovered in 2016 and its spread continue [32]. Also multiple dose of drug use by patients indeed have helped to generate MDR-bacteria suggesting that human intestinal sites are the place of bacterial gene rearrangement and *mdr* gene synthesis [11]. In truth MDR-plasmids are also increased the gene doses of integrases, transposes, recombinases and many IS-elements. Phage therapy, gene medicines and nano-drug carriers may

Table 3: Chromosomal spread of *mdr* genes. GenBank search (www.ncbi.nlm.nih.gov/blast) of whole genomes were indicated the presence of many *mdr* genes in bacterial chromosome to increase the gene dose for antibiotic destruction and to save intestinal bacteria. *acrAB*, *mexAB*, *blaOXA-23*, *PBP2*, *cmr*, *blaCMY*, *norA*, *aph*, *bmr*, *aadA1*, are few *mdr* genes shown here.

Chromosomal spread and localization of multi-drug resistant genes					
Names of the Bacteria	Chromosome acc. no./Size (bp)	<i>mdr</i> gene/% similarity		Position in bacterial chromosome/ Size (bp)	Copy no.
<i>Escherichia coli</i> BW25113	CP009273/4631469	<i>acrAB</i> /100% <i>cmr</i> / 99%	<i>envCD</i> /100%	476132-482170/ 6038 3400624-3411591/ 11k 878844-880412/1568	one three one
<i>Klebsiella pneumoniae</i>	NC_021232/5270770	<i>emrD</i> /99% <i>acrAB</i> /82%		29052-30607/955 4323257-4328383/5127	one two
<i>Stenotrophomonas maltophilia</i> (MDR)	AM743169/4851126	<i>mexAB</i> /80% <i>mexEF</i> /79% <i>aph</i> /80%		4177460-4178947/1487 1879272-1880782/1510 2143348-2144475/1127	two one
<i>E. coli</i> 0103:H2 (Toxin producing)	NC_013353/5449314	<i>acrAB</i> /100% <i>cmr</i> /100%	<i>envCD</i> /98%	489265-495303/6038 4090536-4094991/4455 968010-969578/1568	one one one
<i>Salmonella enterica</i>	CP007557/4685859	<i>acrAB</i> /84% <i>acrB</i> /74% <i>emrD</i> /82%		508579-514081/5507 3444035-3447110/3087 3874357-3875522/1165	two one
<i>Bacillus thuringiensis</i>	NC_005957/5237682	PBP/ n.d. MFS, ABC		2101873-2103330/1457 n.d.	one many
<i>Acinetobacter baumannii</i> TCDC-AB0715 (MDR)	CP002522/4138388	<i>bla_{OXA-23}</i> /99% <i>mexD</i> /66% <i>aadA1/A4</i> /99%		2760564-2761566/1002 2169029-2169609/580 267616-266813/803 etc	one one three
<i>Bacillus subtilis</i>	AP012496/4043042	<i>bmr</i> /99%		2326257-2327658/1401	one
<i>Citrobacter</i> spp.S-77	NZ_DF830265	<i>blaCMY</i> -13/86%		212590-216842/4252	one
<i>S. aureus</i> OCL, MRSA	CP000046/2934567	<i>norA</i> /94% Lactamase-B/ n.d.		775486-778125/2639 73402-74726/424	one one
<i>Klebsiella pneumoniae</i>	FO834906/5438894	<i>acrAB</i> /82% <i>acrB</i> /77%		1458887-1463969/5127 42401264240699/573	three



be alternative approaches to combat MDR horror [32]. Levamisole, Situximab, Prednisone and betaglycan immunomodulators have shown to induce suppressed immunosystem clearing *mdr*-TB by antibody production, T-cell activation and increased phagocytosis and chemotaxis of macrophages [30]. Jemson KC et al. (2015) and others have disclosed the rapid use of bacteriophages in the treatment of MDR infections [31-36]. Gene therapy using interleukin and cytokine genes in expression vectors with fullerenes or DNA-based nanocarriers are centre stage of

development to cure MDR infections [37-39]. I hope MDR mechanisms caused very serious genetic effects in bacteria and huge funding must be allotted for basic research to understand the *mdr* gene creation and its spread into conjugative plasmid and chromosome.

Acknowledgement

I thank Dr J. B. Medda of OAER for financial support and Dr. Bidyut Bondhopadhyay for help during the study.

References

1. Tortora GJ, Funke BR, Case CL (2016) Microbiology: An Introduction 12th edition, London, England, UK.
2. Chakraborty AK (2016) Multi-drug resistant genes in bacteria and 21st Century problems associated with antibiotic therapy. *Biotechnol Ind J* 12: 114.
3. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, et al. (2013) The Comprehensive Antibiotic Resistance Database. *Antimicrob Agents Chemother* 57: 3348-3357.
4. Chakraborty AK (2016) Complexity, heterogeneity, 3-D structures and transcriptional activation of multi-drug resistant clinically relevant bacterial beta-lactamases. *Trends Biotechnol Open access* 2: 1-001.
5. Huang TW, Wang JT, Lauderdal TL, Liao TL, Lai JF, et al. (2013) Complete sequences of two plasmids in a *bla*NDM-1-positive *Klebsiella oxytoca* isolate from Taiwan. *Antimicrob Agents Chemother* 57: 4072-4076.
6. Ouertani R, Jomaa-Jemili MB, Gharsa H, Limelette A, Guillard T, et al. (2017) Prevalence of a New Variant OXA-204 and OXA-48 Carbapenemases Plasmids Encoded in *Klebsiella pneumoniae* Clinical Isolates in Tunisia. *Microb Drug Resist*.

7. Wang J, Li Y, Xu X, Liang B, Wu F, et al. (2017) Antimicrobial resistance of *Salmonella enterica* Serovar Typhimurium in Shanghai, China. *Front Microbiol* 8: 510.
8. Lei CW, Kong LH, Ma SZ, Liu BH, Chen YP, et al. (2017) A novel type 1/2 hybrid Inc C plasmid carrying fifteen antimicrobial resistance genes recovered from *Proteus mirabilis* in China. *Plasmid* 93: 1-5.
9. Bush K, Jacoby GA (2010) Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother* 54: 969-976.
10. Fosberg KJ, Reyes A, Wang B, Selleck EM, Sommer MOA, et al. (2012) The shared antibiotic resistome of soil bacteria and human pathogens. *Science* 337: 1107-1111.
11. Chakraborty AK (2017) Multi-drug resistant bacteria from Kolkata Ganga river with heterogeneous MDR genes have four hallmarks of cancer cells but could be controlled by organic phyto-extracts. *Biochemistry and Biotechnology Research* 5: 11-23.
12. Chakraborty AK (2015) High mode contamination of multi-drug resistant bacteria in Kolkata: mechanism of gene activation and remedy by heterogeneous phyto-antibiotics. *Indian J Biotechnol* 14: 149-159.
13. Chakraborty AK (2016) *In silico* analysis of hotspot mutations in the bacterial NDM-1 and KPC-1 carbapenemases that cause severe MDR phenotypes. *Biochemistry and Biotechnology Research* 4: 17-26.
14. Chakraborty AK, Maity M, Patra S, Mukherjee S, Mandal T (2017) Complexity, heterogeneity and mutational analysis of antibiotic inactivating acetyl transferases in MDR conjugative plasmids conferring multi-resistance. *Res Rev: J Microbiol Biotechnol* 6: 28-43.
15. D Costa VM, King CE, Kalan L, Morar M, Sung WW, et al. (2011) Antibiotic resistance is ancient. *Nature* 477: 457-461.
16. Drawz SM, Bonomo RA (2010) Three decades of beta-lactamase inhibitors. *Clin Microbiol Rev* 23: 160-201.
17. Laxminarayana R (2014) Antibiotic effectiveness: Balancing conservation against innovation. *Science* 345: 1299-1301.
18. Xu ZQ, Flavin MT, Flavin J (2014) Combating multi-drug resistant gram-negative bacterial infection. *Exp Opin Investig Drugs* 23: 163-182.
19. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, et al. (2015) Role of the normal gut microbiota. *World J Gastroenterol* 21: 8787-8803.
20. The human Microbiome Jumstart Reference Strains Consortium (2010) A catalog of reference genomes from human microbiome. *Science* 328: 994-999.
21. Hill MJ (1997) Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 6: S43-S45.
22. Stojanovic RM, de Vos WM (2014) The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol Rev* 38: 996-1047.
23. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, et al. (2013) Richness of human gut microbiome correlates with metabolic markers. *Nature* 500: 541-546.
24. Ram JL, Karim AS, Sandler ED, Kato I (2011) Strategy for microbiome analysis using 16S gene sequence analysis on the Illumina sequencing platform. *Syst Biol Reprod Med* 57: 117-118.
25. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci USA* 74: 5463-5467.
26. Quigley EM (2010) Prebiotics and probiotics modifying and mining the microbiota. *Pharmacol Res* 61: 213-218.
27. Dethlefsen L, Huse S, Sogin ML, Relman DA (2008) The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol* 6: e280.
28. Izadpanah M, Hkalili H (2015) Antibiotic regimens for treatment of infections due to multidrug-resistant Gram-negative pathogens: An evidence-based literature review. *J Res Phar Pract* 4: 105-114.
29. Landman D, Babu E, Shah N, Kelly P, Olawole O, et al. (2012) Transmission of carbapenem-resistant pathogens in New York city hospitals: progress and frustration. *J Antimicrob Chemther* 67: 1427-1431.
30. Zumla A, Rao M, Dodoo E, Maeurer M (2016) Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. *BMC Medicine* 1489: 2-12.
31. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, et al. (2013) Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis* 13: 785-796.
32. Chakraborty AK (2017) Colistin drug resistant determinant Mcr-1 gene spreads in conjugative plasmids creating huge confusion for the treatment of multi-drug resistant infections. *Am Res J Biotechnol* 1: 1-9.
33. Merrill CR, Biswas B, Carlton R, Jensen NC, Creed GJ, et al. (1996) Long-circulating bacteriophage as antibacterial agents. *Proc Natl Acad Sci USA* 93: 3188-3192.
34. Yosef I, Kiro R, Molshanski-Mor S, Edgar R, Qimron U (2014) Different approaches for using bacteriophages against antibiotic resistant bacteria. *Bacteriophage* 4: e28491.
35. Jensen KC, Hair BB, Wienclaw TM, Murdock MH, Hatch JB, et al. (2015) Isolation and host range of bacteriophage with lytic activity against methicillin-resistant *Staphylococcus aureus* and potential use as a fomite decontaminant. *PLoS One* 10: e0131714.
36. Viertel TM, Ritter K, Horz HP (2014) Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. *J Antimicrob Chemother* 69: 2326-2336.
37. Norris JS, Westwater C, Schofield D (2000) Prokaryotic gene therapy to combat multidrug resistant bacterial infection. *Gene Ther* 7: 723-725.
38. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18: 268-281.
39. Chakraborty AK, Roy T, Mondal S (2016) Development of DNA nanotechnology and uses in molecular biology and medicine. *Insights in Biomed* 1: 13.